Travel Medicine

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA ALERT
joint pain
FDA ALERT
FDA Approves First Biosimilar to Tocilizumab to Treat Adults, Pediatric Patients With Arthritis
11/15/2023
Jessica Ganga
In late September, the FDA approved the first biosimilar to tocilizumab to treat adult and pediatric patients with various indications of arthritis.
11/15/2023
FDA alert
test tubes
FDA alert
FDA Approves Biosimilar Treatment for Patients With Multiple Sclerosis
11/14/2023
Jessica Ganga
The FDA has approved the first biosimilar treatment for patients living with relapsing forms of multiple sclerosis.
11/14/2023
FDA alert
test tubes
FDA alert
FDA Approves Biosimilar Treatment for Patients With Multiple Sclerosis
11/14/2023
Jessica Ganga
The FDA has approved the first biosimilar treatment for patients living with relapsing forms of multiple sclerosis.
11/14/2023
FDA alert
test tubes
FDA alert
FDA Approves Biosimilar Treatment for Patients With Multiple Sclerosis
11/14/2023
Jessica Ganga
The FDA has approved the first biosimilar treatment for patients living with relapsing forms of multiple sclerosis.
11/14/2023
FDA alert
test tubes
FDA alert
FDA Approves Biosimilar Treatment for Patients With Multiple Sclerosis
11/14/2023
Jessica Ganga
The FDA has approved the first biosimilar treatment for patients living with relapsing forms of multiple sclerosis.
11/14/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023
FDA Alert
fda
FDA Alert
Tirzepatide Gains FDA Approval for Chronic Weight Management
11/13/2023
Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.
11/13/2023